Overview of erdafitinib price information and current market situation in China

Erdafitinib (Erdafitinib, trade name Balversa), a cutting-edge FGFR inhibitor, has brought new breakthroughs in the field of cancer treatment. However, the high price of its original drug, especially the price of more than 20,000 yuan for 4mg*14 tablets, has caused a considerable financial burden to patients who have long relied on this drug.

In order to alleviate the financial pressure on patients, multiple generic versions of erdafitinib have appeared on the market. The Laos version of Lucius and the ASEAN version of erdafitinib have attracted widespread attention from patients due to their relatively affordable prices and various specifications, such as3mg*28 tablets, 4mg*28 tablets, 5mg*28 tablets, etc. The selling price of these generic drugs is approximately RMB 1,000, and the specific prices may be adjusted due to market fluctuations. In addition, Yaopin International of Bangladesh has also launched generic drugs of erdafitinib, providing 5mg*30 tablets, 4mg*60 tablets and other specifications, priced at more than 1,000 and 2,000 yuan respectively. Compared with the original drug, the cost-effectiveness has been significantly improved.

However, patients still need to be cautious when purchasing generic drugs. At present, erdafitinib has not yet been officially launched in China, and patients need to purchase it through self-pay channels. During this process, it is crucial to choose formal channels for purchase to ensure the authenticity and safety of the medicines. At the same time, patients should always pay attention to the latest selling price information from pharmaceutical manufacturers in order to obtain the most accurate price dynamics.

In general, as an advanced drug in the field of cancer treatment, the high price of erdafitinib as the original drug poses certain challenges to patients. But fortunately, several generic versions of the drug are now on the market, providing patients with more affordable options. During the purchase process, patients should remain vigilant, choose formal channels, and pay close attention to price dynamics to ensure that their rights and interests are not harmed.